medmix’ shareholders approve all proposals at Annual General Meeting 2024

24 April 2024

At today’s annual general meeting (AGM) of medmix Ltd, shareholders approved all proposals of the Board of Directors. medmix will pay an ordinary dividend of CHF 0.50 per share to shareholders.

medmix’ shareholders approved all proposals of the company’s Board of Directors at its AGM 2024. The shareholders approved the Annual Report 2023, including the business review, the financial statements of medmix Ltd, the consolidated financial statements 2023 as well as the appropriation of the annual result.

An ordinary dividend of CHF 0.50 per share will be paid out on April 30, 2024. In consultative votes, the shareholders approved the compensation report and the report on non-financial matters of medmix. Discharge was granted to all members of the Board of Directors and the Executive Committee. The remuneration limits for the Board of Directors for the period from AGM 2024 to AGM 2025, and for the Executive Committee for the financial year 2025, were approved as well.

Rob ten Hoedt was re-elected as Chairman of the Board of Directors, and the shareholders confirmed all members of the Board and the Nomination & Remuneration Committee standing for re-election. Susanne Hundsbaek-Pedersen was newly elected to the Board of Directors. KPMG was confirmed as auditor and Proxy Voting Services GmbH was re-elected as the independent proxy.

The minutes of the AGM 2024 will be published within the statutory period on


Investor Relations: 

Media Relations: 

Key dates in 2024

July 18, 2024     
Half-year results 2024

About medmix

medmix is a global leader in high-precision delivery devices, with leading positions in healthcare, consumer and industrial end-markets. Our customers benefit from our dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 14 production sites worldwide together with our highly motivated and experienced team of nearly 2’700 employees are at service of our customers with uncompromising quality, proximity and agility. medmix is headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX). 

This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein.

Download the Press Release as a PDF